Roche Nimblegen has launched HD2 (2.1 million probes) arrays and services for chromatin immunoprecipitation (Chip-chip).
Nimblegen Chip-chip HD2 arrays now provide more than a five-fold increase in probe density per array, which allows for increasing the coverage of key biological features and decreasing the number of arrays needed to perform whole-genome analysis at high resolution.
Chip-chip is a technique that allows for the high-resolution mapping of chromatin structure including histone modifications, transcription factor and nucleic acid polymerase binding, nucleosome location, and Dnase I hypersensitivity.
These various applications enable researchers to determine what regions of the genome are transcriptionally active, which regions are repressed, and what mechanisms regulate these processes.
Unravelling the fundamental epigenomic and genomic regulatory pathways underlying normal cell growth and tissue differentiation, as well as changes in regulatory control associated with disease, is crucial for the development of drugs that target these pathways.
Roche Nimblegen is recognised as a leading platform for Chip-chip studies and the main array platform used by researchers participating in the Encode consortium, a project aimed at characterising the functional elements of the human genome.
The Nimblegen platform is also widely accepted as the method of choice for Chip-chip experiments with the number of peer-reviewed publications.
Dr Bing Ren, an epigenomics and genomics researcher from the Ludwig Institute, University of California, San Diego School of Medicine, said: 'Nimblegen Chip-chip high-definition 2.1 million probe arrays are a flexible and robust platform for investigating the transcription factor binding sites and chromatin modification patterns in the genome of a variety of model organisms.
'They have been extremely valuable for our research of the transcriptional regulatory elements in the Drosophila, mouse and human genomes.' Customers can access Chip-chip HD2 arrays by ordering arrays, instrumentation and software, and performing the research in their laboratory or core facility, or by simply submitting immunoprecipitated and input samples to the Roche Nimblegen service facility for full service analysis.
Researchers may also target only their genomic regions of interest at any desired tiling resolution by creating a custom design with the support of Nimblegen scientists.
